Skip to main content
An official website of the United States government
Email

NCI Experimental Therapeutics Program (NExT)

Overview:

  • A peer-reviewed program to support the discovery and development of promising agents for cancer therapeutics towards/through the clinic
  • Resources available encompass the end-to-end process: early discovery, candidate selection, IND enabling (cGMP, GLP PK/Tox, filing), FIH, Phase I/II (operated through CTEP)
  • NExT does NOT award grants to the applicants, but rather supports their projects via NCI contracts to advance approved projects in a milestone-driven manner.  Clinical trials may be supported through NCI-funded clinical trial networks
  • Results/products are returned to the applicant PIs and used to support further development by the applicants or in partnership with NCI.
  • Applicants retain ownership of their existing IP– new IP may be shared
  • Currently, NExT application cycles are occurring on an ad hoc basis

 

Typical NExT collaboration sectors that occur at each stage in the pipeline

 

Eligibility Requirements:

  • Researchers in academia, non-profit, and industry
  • Institutions need to have a majority presence in the US
  • Foreign entities/collaborations require additional justifications when applying
  • Only 2 submissions allowed (initial and a re-submission)

About the NExT Program

Email